Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma

Blood Cancer Journal

Volumn 6, Issue 3, 2016, Pages

  Ratner, L ^a   Rauch, D ^a   Abel, H ^a   Caruso, B ^b   Noy, A ^c   Barta, S K ^d   Parekh, S ^d   Ramos, J C ^e   Ambinder, R ^f   Phillips, A ^g   Harding, J ^a   Baydoun, H H ^a   Cheng, X ^a   Jacobson, S ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g New York Presbyterian Morgan Stanley Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; RALTEGRAVIR; VINCRISTINE;

COMPLICATION; GENETICS; HTLV-1 INFECTION; HUMAN; HUMAN T-LYMPHOTROPIC VIRUS 1; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MORTALITY; TREATMENT OUTCOME; VIROLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORTEZOMIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; PREDNISONE; RALTEGRAVIR POTASSIUM; TREATMENT OUTCOME; VINCRISTINE;

EID: 85013692945     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/BCJ.2016.21     Document Type: Letter

References (15)

1. Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y et al. Treatment and survival among 1594 patients with ATL. Blood 2015; 126: 2570–2577.
2. Ratner L, Harrington W, Feng X, Grant C, Jacobson S, Noy A et al. Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma. AIDS Malignancy Consortium. PLoS One 2009; 4: e4420.
3. Seegulam ME, Ratner L. Integrase inhibitors effective against human T-cell leukemia virus type 1. Antimicrob Agents Chemother 2011; 55: 2011–2017.
4. Brunetto GS, Massoud R, Leibovitch EC, Caruso B, Johnson K, Ohayon J et al. Digital droplet PCR (ddPCR) for the precise quantification of human T-lympho-tropic virus 1 proviral loads in peripheral blood and cerebrospinal fluid of HAM/TSP patients and identification of viral mutations. J Neurovirol 2014; 20: 341–351.
5. Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol 2015; 169: 672–682.
6. Tsukasaki K, Utsonomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lym-phoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007; 25: 5458–5864.
7. Cassar O, Einsiedel L, Afonso PV, Gessain A. Human T-cell lymphotropic virus type 1 subtype C molecular variants among indigenous Australians: new insights into the molecular epidemiology of HTLV-1 in Australo-Melanesia. PLoS Negl Trop Dis 2013; 26: e2418.
8. Yamagishi M, Nakano K, Miyake A, Yamochi T, Kagami Y, Tsutsumi A et al. Polycomb-mediated loss of miR-31 activated NIK-dependent NF-kB pathway in adult T cell leukemia and other cancers. Cancer Cell 2012; 21: 121–136.
9. Krejsgaard T, CSV-K CS, Woetmann A, Kneitz H, Eriksen KW, Lovato P et al. Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma. Blood 2009; 113: 5896–5904.
10. Petersen DL, Krejsgaard T, Berthelsen J, Fredholm S, Willerslev-Olsen A, Sibbesen NA et al. B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL). Leukemia 2015; 28: 2109–2112.
11. Soares LR, Tsavaler L, Rivas A, Engleman EG. V7 (CD101) ligation inhibits TCR/CD3-induced IL-2 production by blocking Ca2+ flux and nuclear factor of activated T cell nuclear translocation. J Immunol 1998; 161: 209–217.
12. Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J et al. Integrated molecular analysis of adult T-cell leukemia/lymphoma. Nat Genet 2015; 47: 1304–1315.
13. Bernal-Mizrachi L, Lovly CM, Ratner L. The role of nuclear factor kB-1 and-2-mediated resistance to apoptosis in lymphomas. Proc Natl Acad Sci USA 2006; 103: 9220–9225.
14. Utsunomiya A, Choi I, Chihara D, Seto M. Recent advances in the treatment of adult T-cell leukemia-lymphomas. Cancer Sci 2015; 106: 344–351.
15. Kline J, Bishop MR. Update on checkpoint blockade therapy for lymphoma. J Immunother Cancer 2015; 3: 33.